Naives, Nonresponders, Relapsers: Who Is There Left to Treat?

Archita P. Desai; Nancy Reau

doi:10.1016/j.cld.2011.05.011

Naives, Nonresponders, Relapsers: Who Is There Left to Treat?

Archita P. Desai, Nancy Reau

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

Original language	English (US)
Pages (from-to)	483-495
Number of pages	13
Journal	Clinics in liver disease
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.cld.2011.05.011
State	Published - Aug 2011
Externally published	Yes

Keywords

Epidemiology
Hepatitis C
Non-responders
Pegylated interferon
Relapse
Ribavirin

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2011.05.011

Cite this

@article{949ff591ac4e411a91f995f3aa760b29,

title = "Naives, Nonresponders, Relapsers: Who Is There Left to Treat?",

abstract = "Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.",

keywords = "Epidemiology, Hepatitis C, Non-responders, Pegylated interferon, Relapse, Ribavirin",

author = "Desai, {Archita P.} and Nancy Reau",

year = "2011",

month = aug,

doi = "10.1016/j.cld.2011.05.011",

language = "English (US)",

volume = "15",

pages = "483--495",

journal = "Clinics in liver disease",

issn = "1089-3261",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Naives, Nonresponders, Relapsers

T2 - Who Is There Left to Treat?

AU - Desai, Archita P.

AU - Reau, Nancy

PY - 2011/8

Y1 - 2011/8

N2 - Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

AB - Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

KW - Epidemiology

KW - Hepatitis C

KW - Non-responders

KW - Pegylated interferon

KW - Relapse

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=80051949697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051949697&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2011.05.011

DO - 10.1016/j.cld.2011.05.011

M3 - Review article

C2 - 21867932

AN - SCOPUS:80051949697

SN - 1089-3261

VL - 15

SP - 483

EP - 495

JO - Clinics in liver disease

JF - Clinics in liver disease

IS - 3

ER -

Naives, Nonresponders, Relapsers: Who Is There Left to Treat?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this